Dr. Sayoki Godfrey Mfinanga was invited to present the experience of screening Crypotocaccal meningitis in advanced HIV disease in the International Aids Society meeting symposium in July 2017 in Paris
TRIP Translating Research into Practice | An EDTCP2 Funded Programme | A European Union Supported Programme
Evaluating and Speeding up the adoption of an evidence based approach to caring for advanced stage HIV patients starting antiretroviral therapy in Tanzania.Learn More
Where It All Started
Researchers from the REMSTART team – led by Dr Saidi Egwaga of the Tanzanian Ministry of Health and Social Welfare and Shabbar Jaffar, Professor of Epidemiology at the London School of Hygiene & Tropical Medicine – conducted a randomised trial of 1,999 HIV patients in Tanzania and Zambia between February 2012 and September 2014 using a new approach to caring for patients with advanced HIV which combined community support and screening for cryptococcal meningitis.
The research, published in The Lancet on 10 March 2015, suggests that this low-cost intervention could be an effective approach to reducing HIV-related deaths in Africa.
Following from the positive results, the TRIP study received funding under the second EDCTP programme to assess the approach used in the REMSTART trial on a larger scale in urban and rural settings in Tanzania.
Researchers led by Dr Sayoki Godfrey Mfinanga (National Institute for Medical Research, Tanzania) aims to determine the feasibility of scaling up the TRIP intervention in routine health care and to inform and refine guidelines on HIV services for patients with advanced HIV. It will also determine the cost effectiveness of the TRIP intervention in reducing death in patients with advanced HIV in real health care settings when implemented on a large scale. Moreover, the study will compare differences in effectiveness of the REMSTART and TRIP interventions.
The intervention is implemented in 18 facilities, 12 facilities in Dar es Salaam region (Urban setting) and 6 in Morogoro region (Rural setting).